Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease

Abstract

Neurodegenerative diseases like Alzheimer's and Parkinson's disease are associated with elevated levels of iron, copper, and zinc and consequentially high levels of oxidative stress. Given the multifactorial nature of these diseases, it is becoming evident that the next generation of therapies must have multiple functions to combat multiple mechanisms of disease progression. Metal-chelating agents provide one such function as an intervention for ameliorating metal-associated damage in degenerative diseases. Targeting chelators to adjust localized metal imbalances in the brain, however, presents significant challenges. In this perspective, we focus on some noteworthy advances in the area of multifunctional metal chelators as potential therapeutic agents for neurodegenerative diseases. In addition to metal chelating ability, these agents also contain features designed to improve their uptake across the blood–brain barrier, increase their selectivity for metals in damage-prone environments, increase antioxidant capabilities, lower Aβ peptide aggregation, or inhibit disease-associated enzymes such as monoamine oxidase and acetylcholinesterase.